1. Home
  2. ESEA vs DCTH Comparison

ESEA vs DCTH Comparison

Compare ESEA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Euroseas Ltd. (Marshall Islands)

ESEA

Euroseas Ltd. (Marshall Islands)

HOLD

Current Price

$56.53

Market Cap

432.9M

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.44

Market Cap

289.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESEA
DCTH
Founded
2005
1988
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
432.9M
289.2M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
ESEA
DCTH
Price
$56.53
$10.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$62.00
$22.60
AVG Volume (30 Days)
39.6K
748.8K
Earning Date
11-18-2025
11-04-2025
Dividend Yield
5.08%
N/A
EPS Growth
6.77
N/A
EPS
17.38
0.03
Revenue
$223,794,428.00
$79,603,000.00
Revenue This Year
$10.05
$131.97
Revenue Next Year
N/A
$38.84
P/E Ratio
$3.17
$305.68
Revenue Growth
7.26
251.54
52 Week Low
$26.30
$8.12
52 Week High
$66.00
$18.23

Technical Indicators

Market Signals
Indicator
ESEA
DCTH
Relative Strength Index (RSI) 37.88 62.85
Support Level $58.05 $9.59
Resistance Level $63.99 $10.14
Average True Range (ATR) 2.09 0.44
MACD -0.52 0.16
Stochastic Oscillator 3.75 87.15

Price Performance

Historical Comparison
ESEA
DCTH

About ESEA Euroseas Ltd. (Marshall Islands)

Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: